Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19).

Roberta Giorgione,Daniele Santini,Marco Stellato,Umberto Basso,Davide Bimbatti,Valeria Emma Palmieri,Laura Doni,Lorenzo Antonuzzo,Melissa Bersanelli,Sebastiano Buti,Ugo De Giorgi,Luca Galli,Andrea Sbrana,Raffaele Conca,Claudia Carella,Emanuele Naglieri,Enrico Mini,Sandro Pignata,Giuseppe Procopio,Giandomenico Roviello

Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19).

2021

319Background: Nivolumab is approved in the second or further line of treatment for patients with metastatic renal cell carcinoma (mRCC); cabozantinib is approved in a similar setting of patients. ...

Keywords:

Oncology
Nivolumab
Cabozantinib
Renal cell carcinoma
disease progression
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations